CAR-NK cell therapy for refractory childhood rheumatic diseases
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 5 years old.
- You have a specific type of childhood rheumatic disease (like polyarticular JIA, lupus, or others) that has not responded well to standard treatments.
- Your heart, lungs, liver, and kidneys are working well enough (based on tests).
- You do not have active infections or a history of certain serious infections (like tuberculosis).
- You have not had surgery or a stem cell transplant recently, and you are not taking certain other medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
This early-phase trial tests whether a new type of immune cell (CAR NK) can treat two conditions: antisynthetase antibody syndrome (a rare autoimmune disease) and rheumatoid arthritis. It's for people whose current treatments haven't worked well enough.
This trial tests a new type of cell therapy (CAR-T cells designed to target CD19 and BCMA) for children and teenagers with severe autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this one-time infusion can help control the disease and reduce the need for long-term steroids and other drugs.
Hear when a new Rheumatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.